Top Midday Gainers

MT Newswires Live09-10

Sintx Technologies (SINT) said Monday it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application related to methods of bonding bioactive silicon nitride to zirconia-toughened alumina for biomedical applications.

Shares surged more than 79% as intraday trading volume climbed to more than 62.7 million from a daily average of about 90,000.

Summit Therapeutics (SMMT) said Sunday that a phase 3 trial of its non-small cell lung cancer treatment showed an improved survival rate compared with pembrolizumab monotherapy.

Shares advanced 57% in recent Monday trading as intraday trading volume rose to 39.4 million versus the stock's daily average of under 2.2 million.

Relay Therapeutics (RLAY) reported Monday that patients who received RLY-2608 demonstrated clinically meaningful progression-free survival with a median of 9.2 months despite heavy pre-treatment.

Shares climbed 54%, with intraday trading volume at over 14.6 million compared with a daily average of about 1.1 million.

Price: 5.07, Change: +2.25, Percent Change: +79.79

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466161181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-10 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2466161181","market":"hk","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> Sintx Technologies (SINT) said Monday it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application related to methods of bonding bioactive silicon nitride to zirconia-toughened alumina for biomedical applications.</p><p>Shares surged more than 79% as intraday trading volume climbed to more than 62.7 million from a daily average of about 90,000.</p><p>Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SMMT) said Sunday that a phase 3 trial of its non-small cell lung cancer treatment showed an improved survival rate compared with pembrolizumab monotherapy.</p><p>Shares advanced 57% in recent Monday trading as intraday trading volume rose to 39.4 million versus the stock's daily average of under 2.2 million.</p><p><a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> (RLAY) reported Monday that patients who received RLY-2608 demonstrated clinically meaningful progression-free survival with a median of 9.2 months despite heavy pre-treatment.</p><p>Shares climbed 54%, with intraday trading volume at over 14.6 million compared with a daily average of about 1.1 million.</p><p>Price: 5.07, Change: +2.25, Percent Change: +79.79</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 01:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sintx Technologies (SINT) said Monday it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application related to methods of bonding bioactive silicon nitride to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2466161181","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466161181","pubTimestamp":1725904726,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sintx Technologies (SINT) said Monday it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application related to methods of bonding bioactive silicon nitride to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","RLAY":"Relay Therapeutics","BK4563":"昨日强势股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SINT":"SINTX Technologies Inc","SMMT":"Summit Therapeutics PLC","BK4139":"生物科技"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SINT":1,"SMMT":1,"RLAY":0.9},"content_text":"Sintx Technologies (SINT) said Monday it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application related to methods of bonding bioactive silicon nitride to zirconia-toughened alumina for biomedical applications.Shares surged more than 79% as intraday trading volume climbed to more than 62.7 million from a daily average of about 90,000.Summit Therapeutics (SMMT) said Sunday that a phase 3 trial of its non-small cell lung cancer treatment showed an improved survival rate compared with pembrolizumab monotherapy.Shares advanced 57% in recent Monday trading as intraday trading volume rose to 39.4 million versus the stock's daily average of under 2.2 million.Relay Therapeutics (RLAY) reported Monday that patients who received RLY-2608 demonstrated clinically meaningful progression-free survival with a median of 9.2 months despite heavy pre-treatment.Shares climbed 54%, with intraday trading volume at over 14.6 million compared with a daily average of about 1.1 million.Price: 5.07, Change: +2.25, Percent Change: +79.79","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466161181"}